TY - JOUR
T1 - Comparative Analysis of Different Methods of Ischemia/Reperfusion in Hyperglycemic Stroke Outcomes
T2 - Interaction with tPA
AU - Hafez, Sherif
AU - Hoda, Md Nasrul
AU - Guo, Xinyue
AU - Johnson, Maribeth H.
AU - Fagan, Susan C.
AU - Ergul, Adviye
N1 - Funding Information:
Adviye Ergul is a Research Career Scientist at the Charlie Norwood Veterans Affairs Medical Center in Augusta, GA. This work was supported in part by VA Merit Award (BX000347), VA Research Career Scientists Award, and NIH (R01NS083559) to Adviye Ergul; VA Merit Award (BX000891) and NIH award (NS063965) to Susan C. Fagan; and American Heart Association Predoctoral Fellowship (13PRE17090026) to Sherif Hafez. The contents do not represent the views of the Department of Veterans Affairs or the United States Government.
Publisher Copyright:
© 2015, Springer Science+Business Media New York.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Acute hyperglycemia (HG) exacerbates reperfusion injury and aggravates tissue plasminogen activator (tPA)-induced hemorrhagic transformation (HT). Previous experimental hyperglycemic stroke studies employed very high blood glucose levels and exclusively used suture occlusion model to induce ischemia. Only few studies evaluated HG in embolic stroke and mostly involving the use of 10-fold higher dose of tPA than that is used in patients. However, the interaction between acute HG and low (human) dose tPA in different experimental models of stroke has never been reported. We first tested the impact of the severity of acute HG on stroke outcome. Building upon our findings, we then compared the impact of mild acute HG on neurovascular injury in rats subjected to suture or thromboembolic occlusion with and without low dose tPA. We assessed cerebral blood flow, neurobehavioral outcomes, infarction, hemorrhage, and edema. tPA did not change the infarct size in either control or hyperglycemic animals when compared to no tPA groups. HG increased HT and worsened functional outcomes in both suture and embolic occlusion models. The combination of HG and tPA exacerbated the vascular injury and worsened the neurological deficits more than each individual treatment in both models. Our findings show that the interaction between HG and even low dose tPA has detrimental effects on the cerebrovasculature and functional outcomes independent of the method of reperfusion.
AB - Acute hyperglycemia (HG) exacerbates reperfusion injury and aggravates tissue plasminogen activator (tPA)-induced hemorrhagic transformation (HT). Previous experimental hyperglycemic stroke studies employed very high blood glucose levels and exclusively used suture occlusion model to induce ischemia. Only few studies evaluated HG in embolic stroke and mostly involving the use of 10-fold higher dose of tPA than that is used in patients. However, the interaction between acute HG and low (human) dose tPA in different experimental models of stroke has never been reported. We first tested the impact of the severity of acute HG on stroke outcome. Building upon our findings, we then compared the impact of mild acute HG on neurovascular injury in rats subjected to suture or thromboembolic occlusion with and without low dose tPA. We assessed cerebral blood flow, neurobehavioral outcomes, infarction, hemorrhage, and edema. tPA did not change the infarct size in either control or hyperglycemic animals when compared to no tPA groups. HG increased HT and worsened functional outcomes in both suture and embolic occlusion models. The combination of HG and tPA exacerbated the vascular injury and worsened the neurological deficits more than each individual treatment in both models. Our findings show that the interaction between HG and even low dose tPA has detrimental effects on the cerebrovasculature and functional outcomes independent of the method of reperfusion.
KW - Embolic stroke
KW - Hemorrhagic transformation
KW - Hyperglycemia
KW - Ischemic stroke
KW - Tissue plasminogen activator
UR - http://www.scopus.com/inward/record.url?scp=84939946087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939946087&partnerID=8YFLogxK
U2 - 10.1007/s12975-015-0391-0
DO - 10.1007/s12975-015-0391-0
M3 - Article
C2 - 25683354
AN - SCOPUS:84939946087
SN - 1868-4483
VL - 6
SP - 171
EP - 180
JO - Translational Stroke Research
JF - Translational Stroke Research
IS - 3
ER -